Earnings ·
Cypherpunk Technologies Inc. reported second quarter 2026 financial results, posting net income of $39.4 million or…
LPTXCypherpunk Technologies Inc.
Cypherpunk Technologies Inc. reported second quarter 2026 financial results, posting net income of $39.4 million or $0.18 per diluted share, a reversal from the $16.6 million loss in the prior year period. The improvement was driven by a $46.0 million unrealized gain on its Zcash treasury holdings as ZEC prices rose from $243.35 to $400.09. Cash and cash equivalents stood at $7.6 million, while digital asset receivables totaled $129.4 million. The company increased its ZEC holdings to 323,394.38 coins. Its biotechnology subsidiary, Leap Therapeutics, announced the publication of Phase 2 DeFianCe study results for sirexatamab in metastatic colorectal cancer and reached FDA alignment on a registrational Phase 3 trial design targeting DKK1-high patients. Cypherpunk Technologies operates in the privacy technology and digital asset investment sectors.